Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
“It is an honor to be recognized for such a prestigious award which represents the culmination of the hard work and commitment by our Catalyst teams that helped get us to where we are today,” said
“We are excited to recognize
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved using FIRDAPSE to treat adult patients in Canada with LEMS.
For more information, visit the Company's website at www.catalystpharma.com.
BioFlorida is the voice of Florida’s life sciences industry, representing 6,700 establishments and research organizations in
For more information, visit www.bioflorida.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the
David Schull Russo Partners(858) 717-2310 firstname.lastname@example.org Investor Contact Mary Coleman Catalyst Pharmaceuticals, Inc.(305) 420-3200 email@example.com
Source: Catalyst Pharmaceuticals, Inc.